中国医药
中國醫藥
중국의약
CHINA MEDICINE
2013年
7期
911-912
,共2页
厄贝沙坦氢氯噻嗪片%原发性高血压%血压变异性
阨貝沙坦氫氯噻嗪片%原髮性高血壓%血壓變異性
액패사탄경록새진편%원발성고혈압%혈압변이성
Irbesartan and hydrochlorothiazide tablets%Essential hypertension%Blood pressure variability
目的 观察厄贝沙坦氢氯噻嗪片对原发性高血压病患者血压及血压变异性(BPV)的影响.方法 60例2级原发性高血压患者服用厄贝沙坦氢氯噻嗪片150 mg/d,动态监测治疗前与治疗8周后24h血压,分析比较治疗前后血压及BPV的变化.结果 治疗过程中,3例患者因1周后血压未达标而加服苯磺酸氨氯地平片,退出本研究,有效例数57例.①治疗后与治疗前相比,24 h SBP均值、白昼SBP均值、白昼DBP均值及夜间SBP均值差异有统计学意义[(122 ±8)mm Hg(1 mm Hg=0.133 kPa)比(151 ±24) mm Hg,(127±18) mm Hg比(156±19)mm Hg,(86 ±8)mm Hg比(90±9)mmHg,(118±9)mmHg比(127±8)mm Hg;均P＜0.01].②治疗后BPV均有所减少,24 h SBP变异、白昼SBP和白昼DBP变异、夜间SBP变异差异有统计学意义[(11.2 ±2.3)mm Hg比(14.7±3.1)mm Hg,(15.1±8.5)mm Hg比(18.3±7.0)mm Hg,(9.2±3.2)mm Hg比(10.4 ±2.5) mm Hg; (13.7±7.7)mm Hg比(16.6±7.3)mm Hg;P＜0.05或P＜0.01].结论 厄贝沙坦氢氯噻嗪片不仅能降低血压,而且能降低BPV,改善预后.
目的 觀察阨貝沙坦氫氯噻嗪片對原髮性高血壓病患者血壓及血壓變異性(BPV)的影響.方法 60例2級原髮性高血壓患者服用阨貝沙坦氫氯噻嗪片150 mg/d,動態鑑測治療前與治療8週後24h血壓,分析比較治療前後血壓及BPV的變化.結果 治療過程中,3例患者因1週後血壓未達標而加服苯磺痠氨氯地平片,退齣本研究,有效例數57例.①治療後與治療前相比,24 h SBP均值、白晝SBP均值、白晝DBP均值及夜間SBP均值差異有統計學意義[(122 ±8)mm Hg(1 mm Hg=0.133 kPa)比(151 ±24) mm Hg,(127±18) mm Hg比(156±19)mm Hg,(86 ±8)mm Hg比(90±9)mmHg,(118±9)mmHg比(127±8)mm Hg;均P＜0.01].②治療後BPV均有所減少,24 h SBP變異、白晝SBP和白晝DBP變異、夜間SBP變異差異有統計學意義[(11.2 ±2.3)mm Hg比(14.7±3.1)mm Hg,(15.1±8.5)mm Hg比(18.3±7.0)mm Hg,(9.2±3.2)mm Hg比(10.4 ±2.5) mm Hg; (13.7±7.7)mm Hg比(16.6±7.3)mm Hg;P＜0.05或P＜0.01].結論 阨貝沙坦氫氯噻嗪片不僅能降低血壓,而且能降低BPV,改善預後.
목적 관찰액패사탄경록새진편대원발성고혈압병환자혈압급혈압변이성(BPV)적영향.방법 60례2급원발성고혈압환자복용액패사탄경록새진편150 mg/d,동태감측치료전여치료8주후24h혈압,분석비교치료전후혈압급BPV적변화.결과 치료과정중,3례환자인1주후혈압미체표이가복분광산안록지평편,퇴출본연구,유효례수57례.①치료후여치료전상비,24 h SBP균치、백주SBP균치、백주DBP균치급야간SBP균치차이유통계학의의[(122 ±8)mm Hg(1 mm Hg=0.133 kPa)비(151 ±24) mm Hg,(127±18) mm Hg비(156±19)mm Hg,(86 ±8)mm Hg비(90±9)mmHg,(118±9)mmHg비(127±8)mm Hg;균P＜0.01].②치료후BPV균유소감소,24 h SBP변이、백주SBP화백주DBP변이、야간SBP변이차이유통계학의의[(11.2 ±2.3)mm Hg비(14.7±3.1)mm Hg,(15.1±8.5)mm Hg비(18.3±7.0)mm Hg,(9.2±3.2)mm Hg비(10.4 ±2.5) mm Hg; (13.7±7.7)mm Hg비(16.6±7.3)mm Hg;P＜0.05혹P＜0.01].결론 액패사탄경록새진편불부능강저혈압,이차능강저BPV,개선예후.
Objective To observe the effects of irbesartan and hydrochlorothiazide tablets on blood pressure and blood pressure variability(BPV) of patients with essential hypertension.Methods Sixty patients with essential hypertension were treated with irbesartan and hydrochlorothiazide tablets 150 mg/d,the changes of 24 hours average blood pressure and BPV were compared prior to and after 8 weeks of treatment.Results The 24 hSBP,dSBP,dDBP、nSBP reduced obviously after treatment[(122 ±8)mm Hg (1 mm Hg=0.133 kPa) vs (151 ±24)mm Hg,(127 ±18)mm Hg vs (156 ± 19)mm Hg,(86 ±8)mm Hg vs (90 ±9)mm Hg,(118 ±9)mm Hg vs (127 ±8)mm Hg;all P ＜ 0.01].There was statistically significant difference in 24 hSBPSD,dSBPSD,dDBPSD,nSBPSD between pre and post treatment[(11.2 ±2.3)mm Hg vs (14.7 ±3.1)mm Hg,(15.1 ±8.5)mm Hg vs (18.3 ±7.0)mm Hg,(9.2 ±3.2)mm Hg vs (10.4 ±2.5)mm Hg; (13.7 ±7.7)mm Hg vs (16.6 ±7.3)mm Hg; P＜0.05 or P ＜ 0.01].Conclusion Irbesartan and hydroch-lorothiazide tablets can not only reduce hypertension,but also comtrol BPV and improve prognosis.
